FDA Approves Weekly Injectable Diabetes Drug named Albiglutide

GlaxoSmithKline plc (LSE/NYSE: GSK) Announced that the US Food and Drug Administration (FDA) has approved Tanzeum (algiblutied) for subcutaneous injection use, as a ounce a week treatment for diabetes type 2. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with diabetes mellitus.

Albiglutide is a glucagon-like peptide-1 receptor agonist and is a biological product to be used once a week using a injection pen with 5mm 29-gauge thin-walled needle. Albiglutide improves the important incretin hormone which is often reduced or absent in diabetics type 2 . Tanzeum is not recommended as a first-line therapy for patients with inadequately controlled diabetes. Tanzeum has not been studied in patients with a history of pancreatitis.

Tanzeum is not for treatment of type 1 diabetes mellitus or diabetes ketoacidosis. Tanzeum has not been studied in patients with pre-existing severe gastrointestinal disease and has not been studied in combination with prandial insulin. Tanzeum has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies, including metformin, glimepriride, pioglitazone.

Weekly-Injectable-Diabetes-Drug-named-Albiglutide.jpg

 

 

 

 

Image credit: flickr.com

Comments

comments

Meet the Author

Marcos Taquechel

Marcos works as an RN in sub acute care and with the elderly. He believes you can heal yourself. By providing good useful information, others can use and transform their life. He keep searching for natural healing that produce results. Please leave a comment. Thank you

2 comments… add one

Leave a Comment